Value of carcinoembryonec antigen in biochemotherapy response monitoring in patients with Her-2-positive advanced breast cancer.
- Author:
Xu-jian CHEN
1
,
2
;
Rong-cheng LUO
;
Feng-sheng CHEN
;
Xiao-hua CHEN
;
Bin-mei ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antibodies, Monoclonal, Humanized; administration & dosage; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Breast Neoplasms; drug therapy; genetics; Carcinoembryonic Antigen; blood; Female; Humans; Middle Aged; Monitoring, Physiologic; Paclitaxel; administration & dosage; Receptor, ErbB-2; genetics; Trastuzumab
- From: Journal of Southern Medical University 2010;30(6):1418-1421
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the value of serum carcinoembryonec antigen (CEA) in monitoring the response to biochemotherapy by Herceptin plus taxol (TAX) in patients with Her-2-positive advanced breast cancer.
METHODSThe changes in serum CEA level were investigated retrospectively after two cycles of biochemotherapy in 83 patients with Her-2-positive advanced breast cancer. The correlations between the changes and radiological objective response were analyzed.
RESULTSAfter two cycles of biochemotherapy, the clinical benefit rate (CBR) was 81.9%. In the 60 patients with lowered CEA level, the CBR was 85.0% (51/60), with a non-response rate of 15.0% (9/60); in contrast, the CBR was only 34.8% in 23 patients with elevated CEA, with a non-response rate of 65.2%, showing significant difference between the two groups (P<0.05).
CONCLUSIONSerum CEA level can be used to monitor the therapeutic effect of biochemotherapy in patients with Her-2-positive advanced breast cancer.
